Reasons for discontinuing clozapine: Matched, case-control comparison with risperidone long-acting injection

British Journal of Psychiatry

Volumn 194, Issue 2, 2009, Pages 165-167

  Taylor, David M ^a,b   Douglas Hall, Petrina ^c   Olofmjana, Banke ^c   Whiskey, Eromona ^c   Thomas, Arwel ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LONG ACTING DRUG; RISPERIDONE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; ASPHYXIA; BIPOLAR DISORDER; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG OVERDOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT DECISION MAKING; PNEUMONIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEPSIS; SIDE EFFECT; STANDARDIZED MORTALITY RATIO; SUDDEN DEATH; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CAUSE OF DEATH; CLOZAPINE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TREATMENT REFUSAL; YOUNG ADULT;

EID: 60149100470     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.051979     Document Type: Article

References (26)

1. Atkin k, Kendall F, Gould D, Freeman H, Lieberman J, O'sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-8.
2. Devinsky 0, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369-71.
3. Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry 2006; 6: 43.
4. Killian JG, Kerr K, Lawrence c, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancer 1999; 354: 1841-5.
5. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172-6.
6. Hagg S, Spigset o, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-6.
7. Sernyak MJ, Desai R, Stolar M, Rosenheck R. impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931-7.
8. walker AM, Lanza ll, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7.
9. Meltzer HY, Alphs l, Green Al, Altamura AC, Anand R, Bertoldi A. Clozapine treatment for suicidally in schizophrenia: international Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
10. Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM. Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 2007; 68: 1027-30.
11. Young cl, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr scand 2006; 114: 14-20.
12. Office for National Statistics. Mortality statistics, 2002. Series DHl, no. 35. ONS, 2003.
13. Osby u, Correia N, Brandt l, Ekbom A, Sparen p. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21-8.
14. Joukamaa m, Heliovaara M, Knekt p, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-7.
15. Sana S, Chant D, McGrath j. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-31.
16. Henderson DC, Cagliero E, Gray c, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am 1 Psychiatry 2000; 157: 975-81.
17. Curkendall SM, Mo j, Glasser DB, Rose Stang m, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004; 65: 715-20.
18. Knol W, van Marum RJ, Jansen PA, Souverein pc, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56: 661-6.
19. Hinkes R, Quesada TV, Currier MB, Gonzalez-Bianco m. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol 1996; 16: 462-3.
20. Derenne JL, Baldessarini rj. Clozapine toxicity associated with smoking cessation: case report. Am J Ther 2005; 12: 469-71.
21. Zullino DF, Delessert D, Eap CB, Preisig m, Baumann p. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine, int Clin Psychopharmacol 2002; 17: 141-3.
22. Procyshyn RM, Tse G, Sin 0, Flynn S. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 2002; 12: 77-80.
23. Paton c, Esop R, Young c, Taylor D. obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004; 110: 299-305.
24. Taylor D, Young c, Esop R, Paton c, Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152-6.
25. Barnes tr, Paton c, Hancock E, Cavanagh mr, Taylor D, Lelliott p. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118: 26-33.
26. Henderson DC, Kunkel l, Nguyen DD, Borba CP, Daley tb, Louie PM, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113: 142-7.